{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:17:39Z","timestamp":1792783059620,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University College Dublin","id":[{"id":"https:\/\/ror.org\/05m7pjf47","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in heart failure (HF), but their effect on arrhythmias is less clear. Patients with implantable cardioverter-defibrillators (ICDs) are a high risk population for ventricular arrhythmias. However, the effects of SGLT2 inhibitors on ventricular arrhythmias remains a source of debate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Scopus, and Cochrane databases from inception to August 19, 2025, for studies evaluating SGLT2 inhibitors and arrhythmic\/cardiovascular outcomes. Pooled mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI) were calculated using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1,605 patients were included in our analysis. SGLT2 inhibitors was associated with a significant reduction in the risk of ventricular arrhythmia (RR: 0.38; 95% CI: 0.17 to 0.81;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), ventricular tachycardia (RR: 0.60; 95% CI: 0.41 to 0.88;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009), and supraventricular tachycardia (RR: 0.67; 95% CI: 0.47 to 0.95;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). No significant effect was observed on non-sustained VT (RR: 0.94; 95% CI: 0.52 to 1.67;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.83). However, SGLT2 inhibitors were also associated with a significant reduction in ICD shocks (RR: 0.49; 95% CI: 0.38 to 0.64;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001) and cardiovascular mortality (RR: 0.39; 95% CI: 0.22 to 0.70;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In ICD patients, SGLT2 inhibitor therapy significantly reduced ventricular arrhythmias, discrete sustained VT, and SVT, with secondary analyses suggesting fewer ICD shocks and reduction in CV mortality in the patients with ICD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10840-026-02274-1","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:25:45Z","timestamp":1772259945000},"page":"2031-2039","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The impact of sodium glucose cotransporter-2 inhibitors on ventricular arrhythmia in patients with implantable cardioverter-defibrillators: a meta analysis"],"prefix":"10.1007","volume":"69","author":[{"given":"Mayank","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle Serafim","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oybek","family":"Nazarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kruti","family":"Matawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Chahodiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubran Al","family":"Hooti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hritvik","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Goldbarg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"1","key":"2274_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/jcdd4010003","volume":"4","author":"D Masarone","year":"2017","unstructured":"Masarone D, Limongelli G, Rubino M, Valente F, Vastarella R, Ammendola E, et al. Management of Arrhythmias in HF. J Cardiovasc Dev Dis. 2017;4(1):3.","journal-title":"J Cardiovasc Dev Dis"},{"key":"2274_CR2","doi-asserted-by":"publisher","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB et al. 2017 AHA\/ACC\/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation [Internet]. 2018 Sept 25 [cited 2025 Oct 17];138(13). Available from: https:\/\/www.ahajournalshttps:\/\/doi.org\/10.1161\/CIR.0000000000000548","DOI":"10.1161\/CIR.0000000000000548"},{"key":"2274_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1161\/JAHA.121.023743","volume":"11","author":"KC Bilchick","year":"2022","unstructured":"Bilchick KC, Wang Y, Curtis JP, Shadman R, Dardas TF, Anand I, et al. Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter-Defibrillator Generator Changes. J Am Heart Assoc. 2022;11:13.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2274_CR4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.121.056072","volume":"145","author":"A Yafasova","year":"2022","unstructured":"Yafasova A, Butt JH, Elming MB, Nielsen JC, Haarbo J, Videb\u00e6k L, et al. Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With Nonischemic Systolic HF on Mortality). Circulation. 2022;145(6):427\u201336.","journal-title":"Circulation"},{"issue":"10","key":"2274_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa071098","volume":"359","author":"JE Poole","year":"2008","unstructured":"Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic Importance of Defibrillator Shocks in Patients with HF. N Engl J Med. 2008;359(10):1009\u201317.","journal-title":"N Engl J Med"},{"issue":"6","key":"2274_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.hlc.2023.02.009","volume":"32","author":"J Mundisugih","year":"2023","unstructured":"Mundisugih J, Franke KB, Tully PJ, Munawar DA, Kumar S, Mahajan R. Prevalence and prognostic implication of atrial fibrillation in HF subtypes: systematic review and meta-analysis. Heart Lung Circ. 2023;32(6):666\u201377.","journal-title":"Heart Lung Circ"},{"issue":"9","key":"2274_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-023-01887-4","volume":"83","author":"J Patel","year":"2023","unstructured":"Patel J, Rassekh N, Fonarow GC, Deedwania P, Sheikh FH, Ahmed A, et al. Guideline-Directed Medical Therapy for the Treatment of HF with Reduced Ejection Fraction. Drugs. 2023;83(9):747\u201359.","journal-title":"Drugs"},{"key":"2274_CR8","unstructured":"Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport 2 (SGLT2) Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Oct 17]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576405\/"},{"issue":"21","key":"2274_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with HF and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"2274_CR10","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in HF. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"16","key":"2274_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in HF with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"1","key":"2274_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","volume":"23","author":"J Liao","year":"2024","unstructured":"Liao J, Ebrahimi R, Ling Z, Meyer C, Martinek M, Sommer P, et al. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of >\u200980,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death). Cardiovasc Diabetol. 2024;23(1):78.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"2274_CR13","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2409258","volume":"24","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang X, Zhang W, Li J, Weng W, Li Q. Association of sodium-glucose cotransporter 2 inhibitors (SGLT2i) with cardiac arrhythmias: a systematic review and meta-analysis of cardiovascular outcome trials. Rev Cardiovasc Med. 2023;24(9):258. https:\/\/doi.org\/10.31083\/j.rcm2409258.","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"2274_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12933-024-02309-9","volume":"28","author":"S Fujiki","year":"2024","unstructured":"Fujiki S, Iijima K, Nakagawa Y, Takahashi K, Okabe M, Kusano K, et al. Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial. Cardiovasc Diabetol. 2024;28(1):224.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2274_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13643-025-02766-7","volume":"14","author":"M Lin","year":"2025","unstructured":"Lin M, Zhang S, Zhang L, Yang C, Luo Y, Peng Y, et al. Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in HF patients: a meta-analysis of randomized controlled trials. Syst Rev. 2025;14(1):31.","journal-title":"Syst Rev"},{"key":"2274_CR16","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;n71.","DOI":"10.1136\/bmj.n71"},{"key":"2274_CR17","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M et al. Cochrane Handbook for Systematic Reviews of Interventions: Current Version [Internet]. Available from: www.cochrane.org\/handbook"},{"issue":"7414","key":"2274_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"12","key":"2274_CR19","doi-asserted-by":"publisher","first-page":"10191","DOI":"10.1007\/s00210-024-03224-2","volume":"397","author":"F Abedi","year":"2024","unstructured":"Abedi F, Mohammadpour AH, Ghavami V, Heidari-Bakavoli A, Jomezadeh V, Tayyebi M. The effects of empagliflozin on ventricular arrhythmias in HF patients with an implantable cardioverter-defibrillator: a double-blind randomized controlled trial. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(12):10191\u2013201.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2274_CR20","doi-asserted-by":"crossref","unstructured":"Erbay I, Gudul NE, Kokturk U, Aladag P, Kandazoglu M, Avci A. The Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Implantable Cardioverter Defibrillator Shocks in HF Patients Undergoing Diuretic Therapy. Med Princ Pract. 2024;1\u201312.","DOI":"10.1159\/000542172"},{"issue":"11","key":"2274_CR21","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1007\/s13300-020-00924-9","volume":"11","author":"S Fujiki","year":"2020","unstructured":"Fujiki S, Iijima K, Okabe M, et al. Placebo-controlled, double-blind study of empagliflozin and implantable cardioverter-defibrillator (EMPA-ICD) in patients with type 2 diabetes. Diabetes Ther. 2020;11(11):2739\u201355. https:\/\/doi.org\/10.1007\/s13300-020-00924-9. Trial registration: jRCTs031180120.","journal-title":"Diabetes Ther"},{"issue":"3","key":"2274_CR22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/jcm14030786","volume":"14","author":"L Katov","year":"2025","unstructured":"Katov L, Rostan J, Teumer Y, Diofano F, Bothner C, Rottbauer W, et al. Antiarrhythmic Effects of SGLT2 Inhibitors on Supraventricular Tachyarrhythmias in Patients with HFrEF. J Clin Med. 2025;14(3):786.","journal-title":"J Clin Med"},{"key":"2274_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107759","volume":"216","author":"C Sardu","year":"2025","unstructured":"Sardu C, Trotta MC, Marfella LV, D\u2019Amico G, La Marca C, Mauro C, et al. Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator. Pharmacol Res. 2025;216:107759.","journal-title":"Pharmacol Res"},{"key":"2274_CR24","doi-asserted-by":"publisher","unstructured":"Benedikt M, Oulhaj A, Rohrer U, Manninger M, Tripolt NJ, Pferschy PN et al. Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs\/CRT-Ds. NEJM Evid [Internet]. 2024 Sept 24 [cited 2025 Oct 17];3(10). Available from: https:\/\/evidence.nejmhttps:\/\/doi.org\/10.1056\/EVIDoa2400147","DOI":"10.1056\/EVIDoa2400147"},{"issue":"12","key":"2274_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","volume":"346","author":"AJ Moss","year":"2002","unstructured":"Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. N Engl J Med. 2002;346(12):877\u201383.","journal-title":"N Engl J Med"},{"issue":"3","key":"2274_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive HF. N Engl J Med. 2005;352(3):225\u201337.","journal-title":"N Engl J Med"},{"key":"2274_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2025.06.028","author":"AB Curtis","year":"2025","unstructured":"Curtis AB, Auricchio A, Mittal S, Pickett RA, Holmes TR, Jacobsen LD, et al. Contemporary implantable cardioverter-defibrillator benefit. JACC: Clinical Electrophysiology. 2025. https:\/\/doi.org\/10.1016\/j.jacep.2025.06.028.","journal-title":"JACC: Clinical Electrophysiology"},{"issue":"1","key":"2274_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10840-024-01873-0","volume":"68","author":"DM Frodi","year":"2024","unstructured":"Frodi DM, Diederichsen SZ, Xing LY, Spona DC, Jacobsen PK, Risum N, et al. Incidence and risk factors for first and recurrent ICD shock therapy in patients with an implantable cardioverter defibrillator. J Interv Card Electrophysiol. 2024;68(1):125\u201339.","journal-title":"J Interv Card Electrophysiol"},{"issue":"17","key":"2274_CR29","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of HF. J Am Coll Cardiol. 2022;79(17):e263\u2013421.","journal-title":"J Am Coll Cardiol"},{"key":"2274_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101615","author":"V Jaiswal","year":"2025","unstructured":"Jaiswal V, Ang S, Kumar D, et al. Sodium-glucose cotransporter-2 inhibitors and arrhythmias: a meta-analysis of 38 randomized controlled trials. JACC Adv. 2025. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101615.","journal-title":"JACC Adv"},{"issue":"3","key":"2274_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RCI, Fiolet JWT, Stienen GJM, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568\u201373.","journal-title":"Diabetologia"},{"issue":"9","key":"2274_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","volume":"11","author":"J Jordan","year":"2017","unstructured":"Jordan J, Tank J, Heusser K, Heise T, Wanner C, Heer M, et al. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. J Am Soc Hypertens. 2017;11(9):604\u201312.","journal-title":"J Am Soc Hypertens"},{"issue":"3","key":"2274_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na\u2009+\u2009and vasodilation. Diabetologia. 2018;61(3):722\u20136.","journal-title":"Diabetologia"},{"issue":"9","key":"2274_CR34","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","volume":"28","author":"PS Jhund","year":"2022","unstructured":"Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with HF: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28(9):1956\u201364.","journal-title":"Nat Med"},{"issue":"7","key":"2274_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF, et al. Effect of SGLT2 inhibitors on HF outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12(7):447\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2274_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cjco.2019.04.003","volume":"1","author":"CJ MacIntyre","year":"2019","unstructured":"MacIntyre CJ, Sapp JL, Abdelwahab A, Al-Harbi M, Doucette S, Gray C, et al. The Effect of Shock Burden on HF and Mortality. CJC Open. 2019;1(4):161\u20137.","journal-title":"CJC Open"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-026-02274-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-026-02274-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-026-02274-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:54:39Z","timestamp":1792572879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-026-02274-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2274"],"URL":"https:\/\/doi.org\/10.1007\/s10840-026-02274-1","relation":{},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No human participants were involved in this study and no new data was synthesized.","order":1,"name":"Ethics","label":"Approval of the research protocol","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":3,"name":"Ethics","label":"Animal Studies","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":4,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}